Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine MRS and Biomarkers in Alzheimer's Disease
NCT00551161Phase 4Completed
- Sponsor
- Northwell Health
- Start
- Aug 2007
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of memantine in Alzheimer's disease (AD), sponsored by Northwell Health. Primary endpoint: Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI at 48 weeks. Started Aug 2007; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00551161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551161.